Exploiting Biomarkers for A Personalized Healthcare Approach to the Development of Ipatasertib

Time: 2:00 pm
day: Day Two

Details:

  • Advancing understanding of alterations of the PI3K/AKT pathway in human cancer and the differences in frequencies of alterations in different cancer types
  • Determining the role of PI3K/AKT activation in adaptive resistance in current treatment standards to inform future resistance strategies
  • Developing flexible patient selection strategies based on disease and combination context to overcome resistance

Speakers: